Supplementary material corresponding to the article 'free cortisol and free 21-deoxycortisol in the clinical evaluation of congenital adrenal hyperplasia'

Adriaansen, B.P.H.

Utari, A.

Olthaar, A.J.

van der Steen, R.C.B.M.

Pijnenburg-Kleizen, K.J.

Berkenbosch, L.

Span, P.N.

Sweep, F.C.G.J.

Claahsen - van der Grinten, H.L.

van Herwaarden, A.E.

Supplementary material corresponding to the article ‘Free cortisol and free 21-deoxycortisol in the clinical evaluation of congenital adrenal hyperplasia’ (DOI: 10.1210/clinem/dgae591) published in The Journal of Clinical Endocrinology & Metabolism (JCEM). This study aimed to measure free cortisol and free 21-deoxycortisol concentrations in patients with congenital adrenal hyperplasia and compare this to levels in patients with non-classic congenital adrenal hyperplasia, patients with other forms of adrenal insufficiency, and controls. This collection includes the supplementary materials: - Table S1: Genetic analyses of included CAH patients (n=34) with predicted phenotype based on residual enzyme activity and literature. - Table S2: liquid chromatography tandem mass spectrometry setting for measuring total cortisol and 21-deoxycortisol - Table S3: liquid chromatography tandem mass spectrometry setting for measuring total cortisol and 21-deoxycortisol - Figure S1: Flowchart of included patients for this research - Figure S2: Percentage of free cortisol before (T0) and after (T60) administration of Synacthen® in patients with classic congenital adrenal hyperplasia (CAH), non-classic congenital adrenal hyperplasia (NCCAH), adrenal insufficiency but not CAH (AI), and controls. (S2A) Free cortisol percentage at T0; (S2B) Change in free cortisol percentages between T0 and T60; (S2C) Free cortisol percentage at T60. - Reference list of the references used in this document.